Syndax Pharmaceuticals (FRA:1T3) Total Receivables: €52.5 Mil (As of Mar. 2026)


FRA:1T3 Syndax Pharmaceuticals Inc FRA:1T3
25 GF Score
Price €21.28
! 9 Warning Signs
View Full Analysis

What is Syndax Pharmaceuticals Total Receivables?

Syndax Pharmaceuticals FRA:1T3 -0.61% 25 Total Receivables is €52.5 Mil as of Mar. 2026. GuruFocus rates FRA:1T3 with a GF Score™ of 25/100. The stock has 9 warning signs investors should review.

Syndax Pharmaceuticals's Total Receivables for the quarter that ended in Mar. 2026 was €52.5 Mil.

Syndax Pharmaceuticals Total Receivables Related Terms

Syndax Pharmaceuticals Total Receivables Historical Data

* Premium members only.

The historical data trend for Syndax Pharmaceuticals's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syndax Pharmaceuticals Total Receivables Chart

Syndax Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.38 3.83 1.13 13.25 60.03

Syndax Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.87 32.45 36.69 60.03 52.50
FRA:1T3
25GF Score
Syndax Pharmaceuticals Inc FRA:1T3
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syndax Pharmaceuticals Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €52.5 Mil mean?
Syndax Pharmaceuticals (FRA:1T3) has a Total Receivables of €52.5 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Syndax Pharmaceuticals and its competitors.
Is Syndax Pharmaceuticals' Total Receivables too high?
Syndax Pharmaceuticals' current Total Receivables is €52.5 Mil. Overall, Syndax Pharmaceuticals has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Syndax Pharmaceuticals' Total Receivables compare to IOVA and GLUE?
Syndax Pharmaceuticals' Total Receivables of €52.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Syndax Pharmaceuticals and its competitors. Syndax Pharmaceuticals's current Total Receivables is €52.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syndax Pharmaceuticals stock overvalued right now?
Syndax Pharmaceuticals (FRA:1T3) has a current Total Receivables of €52.5 Mil. The current Total Receivables is €52.5 Mil. Syndax Pharmaceuticals' overall GF Score™ is 25/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Syndax Pharmaceuticals (FRA:1T3), the current Total Receivables is €52.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syndax Pharmaceuticals Business Description

Other Exchanges SNDX:USA1T3:Germany
Address 730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
25GF Score

Get the complete analysis for FRA:1T3

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.28
Price